USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
12 Jun 2024 | 03:00 PM GMT

DTx: A Comeback?

Anchored by:

Gabriele Tundo
Partner
PLEXUS VENTURES

Participants:

Gabriele Tundo PartnerPlexus Ventures
Gabriele Tundo
PartnerPlexus Ventures
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Amy O'Donoghue Digital Health AnalystHealthXL
Amy O'Donoghue
Digital Health AnalystHealthXL
Benjamin Alouf Chief Medical OfficerFloreo
Benjamin Alouf
Chief Medical OfficerFloreo
Jean Ledger Research and evaluation consultantAdora Digital Health
Jean Ledger
Research and evaluation consultantAdora Digital Health
Jeff Weness VP Growth and StrategyRefinedScience
Jeff Weness
VP Growth and StrategyRefinedScience
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Tessy Huss Director of Strategy , HLTH CommunityHLTH Community
Tessy Huss
Director of Strategy , HLTH CommunityHLTH Community

About this Meeting

Digital therapeutics (DTx) has been a rapidly growing sector in healthcare, attracting significant investment. However, recent challenges, including market conditions and financing difficulties, have cast a shadow over the industry. 


Many DTx companies are facing cash shortages and are unable to allocate funds for essential activities like clinical research and commercialisation. Additionally, the lack of a clear reimbursement frameworks in many parts of the world has hindered the adoption of DTx products, despite their potential to improve healthcare outcomes. 


In order to succeed, DTx companies need to focus on the economic viability of their products and work towards establishing reimbursement pathways. Industry collaboration, policy changes, and education are necessary to ensure that these innovative solutions can benefit patients and the healthcare system as a whole.


Join this meeting to collaboratively shape the next phase of DTx: 

  • What are some challenges facing the digital therapeutics (DTx) industry and its growth? 
  • How can DTx companies overcome cash shortages and allocate funds for essential activities? 
  • What steps can be taken to establish clear reimbursement pathways for DTx products and improve their adoption in healthcare?  
  • Is a comeback on the cards for DTx?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.